Solventum Corporation
SOLV Healthcare Medical Instruments & Supplies
Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024. In the quarter to June 2026, revenue grew 2.22%, EPS grew 1.92%, free cash flow grew 144.1% and total debt fell 32.4%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow SOLV
Solventum Corporation (SOLV) EPS (diluted)
Solventum Corporation's EPS (diluted) for fiscal 2025 was $8.88, up 221.7% from $2.76 in fiscal 2024. Over the twelve months to 30 June 2026 it was $8.18. Solventum Corporation ranks 3rd of 49 Medical Instruments & Supplies companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $8.88 | 221.74% |
| FY2024 | $2.76 | (64.59%) |
| FY2023 | $7.79 | 0.22% |
| FY2022 | $7.78 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $0.53 | 657.14% |
| Mar 2026 | $0.07 | (80.56%) |
| Dec 2025 | $0.36 | (95.01%) |
| Sep 2025 | $7.22 | 1,315.69% |
| 10 more quarters | Free account |
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| SOLV Solventum Corporation | $8.18 |
| WST West Pharmaceutical Services, Inc. compare | $7.81 |
| ALGN Align Technology, Inc. compare | $5.75 |
| ATR AptarGroup, Inc. compare | $5.53 |
| COO The Cooper Companies, Inc. compare | $2.93 |
| ALC Alcon compare | $1.31 |
| RGEN Repligen Corporation compare | $0.73 |
| AVTR Avantor, Inc. compare | −$0.84 |
| BAX Baxter International Inc. compare | −$2.07 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on SOLV
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement